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Equine infectious anemia virus (EIAV) Rev is an essential regulatory protein that facilitates expression of
viral mRNAs encoding structural proteins and genomic RNA and regulates alternative splicing of the bicistronic tat/rev mRNA. EIAV Rev is characterized by a high rate of genetic variation in vivo, and changes in Rev
genotype and phenotype have been shown to coincide with changes in clinical disease. To better understand
how genetic variation alters Rev phenotype, we undertook deletion and mutational analyses to map functional
domains and to identify specific motifs that are essential for EIAV Rev activity. All functional domains are
contained within the second exon of EIAV Rev. The overall organization of domains within Rev exon 2 includes
a nuclear export signal, a large central region required for RNA binding, a nonessential region, and a
C-terminal region required for both nuclear localization and RNA binding. Subcellular localization of green
fluorescent protein-Rev mutants indicated that basic residues within the KRRRK motif in the C-terminal
region of Rev are necessary for targeting of Rev to the nucleus. Two separate regions of Rev were necessary for
RNA binding: a central region encompassing residues 57 to 130 and a C-terminal region spanning residues 144
to 165. Within these regions were two distinct, short arginine-rich motifs essential for RNA binding, including
an RRDRW motif in the central region and the KRRRK motif near the C terminus. These findings suggest that
EIAV Rev utilizes a bipartite RNA-binding domain.
tribute to Rev selection in vivo requires identification of the
functional domains and motifs that mediate EIAV Rev activity.
The Rev/Rex proteins of complex retroviruses differentially
regulate expression of incompletely spliced mRNAs encoding
virion structural and enzymatic proteins and progeny RNA
molecules (reviewed in reference 17). The prototypical member of this family, human immunodeficiency type 1 (HIV-1)
Rev, binds to the viral pre-mRNA at a specific sequence called
the Rev-responsive element (RRE) (15, 48), multimerizes (37,
47), and facilitates export of incompletely spliced RNAs from
the nucleus via a nucleoporin pathway distinct from that used
by most cellular mRNAs (18, 19). Mutational analyses indicate
that the activities of HIV-1 Rev are mediated by discrete functional domains, including an N-terminal arginine-rich RNAbinding motif (ARM), which also functions as a nuclear localization signal (NLS) (24, 32), and a C-terminal leucine-rich
nuclear export signal (NES) (18, 19). EIAV Rev is a 165amino-acid protein translated from exons 3 and 4 of a multiply
spliced, 4-exon, bicistronic mRNA that also encodes the transactivating protein Tat (Fig. 1A) (12). EIAV Rev is functionally
homologous to HIV-1 Rev (20, 33) but is less well characterized. The N-terminal leucine-rich NES, which maps to amino
acids 31 to 55 (Fig. 1B) (20, 23, 33), is similar to other leucinerich viral and cellular export proteins that interact with the
nuclear exporter CRM1; however, EIAV Rev is atypical in
the spacing of the leucine residues within the NES (23, 38).
The C-terminal basic region has been found to be important
for nuclear localization, while the central region of the protein
has been implicated in RNA binding (14, 23).

Equine infectious anemia virus (EIAV) infection of horses
can result in a rapid, variable, and dynamic disease course.
Moreover, horses that survive the early clinical episodes of
disease are generally able to control virus replication and
remain clinically normal, inapparent carriers of EIAV. The
unique features of clinical disease, and the ability of some
infected horses to eventually control virus replication, provide an excellent system for longitudinal analyses of virus
and host factors important in lentivirus persistence and pathogenesis. Genetic diversity is a hallmark of lentiviruses and is considered an important mechanism of virus persistence and pathogenesis. Previous studies have identified a high rate of genetic
variation in EIAV in the region overlapped by the transmembrane protein gp45 (TM) and the major exon of Rev (2, 30).
Genetic variation in rev/tm can significantly alter Rev activity
(7), and in vivo studies suggest that changes in Rev phenotype
correlate with changes in the clinical stage of disease (4, 6). In
particular, Rev is significantly less active during the inapparent
compared to the chronic stage of disease, suggesting that the
Rev phenotype contributes to selection of virus variants in
vivo. Insight into the genetic changes and factors that con-
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FIG. 1. Organization and splicing patterns of EIAV and the EIAV Rev amino acid sequence. (A) Schematic of the EIAV genome showing
open reading frames (ORF) and predominant mRNAs (a to e) isolated from virus-infected tissue culture cells (27). Regulatory proteins Tat
(T) and Rev (r, rev) are translated from the four-exon mRNA (a). In the presence of Rev, EIAV exon 3 is skipped, resulting in a three-exon
multiply spliced mRNA that encodes only Tat (b). Structural proteins and progeny RNA molecules are translated from singly spliced (d) and
unspliced mRNAs (e). Ttm, a protein of unknown function (5), is encoded by a two-exon mRNA (c). (B) The amino acid sequence of the wild-type
EIAV Rev H21 (7) is shown and numbered 1 to 165. The nuclear export signal (aa 31 to 55) is boxed.

In addition to promoting nuclear export of incompletely
spliced RNA, EIAV Rev regulates alternative splicing of the
viral RNA. In the presence of Rev, the multiply spliced
mRNA, which lacks exon 3 (Fig. 1A), is produced (34). Exon
3 contains the translational start site for Rev, and alternative
splicing was originally proposed as a novel mechanism for
autoregulation of Rev expression (21, 23). Exon 3 is flanked
by a suboptimal splice acceptor and contains a purine-rich
exonic splicing enhancer (ESE) that interacts with the SR
protein SF2/ASF (21). The ESE also functions as an EIAV
RRE (6), and we have suggested that EIAV Rev mediates
alternative splicing of exon 3 through protein-RNA interactions required for efficient export of incompletely spliced
viral RNAs. While the exact mechanism of alternative splicing is not known, current models (6, 14) agree that alternative splicing requires both nuclear localization and RNA
binding and perhaps an as yet unidentified domain(s) of Rev
that interacts directly with SF2/ASF and/or other cellular
splicing factors. To date, the specific amino acids that mediate EIAV Rev nuclear import, RNA binding, and alternative splicing have not been identified. Using a series of
deletions and mutations in EIAV Rev cDNA, we mapped
functional domains of EIAV Rev and identified specific
motifs required for nuclear localization and RNA binding.
Two noncontiguous, short ARMs were required for RNA
binding, suggesting that EIAV Rev contains a bipartite
RNA-binding domain.

MATERIALS AND METHODS
Construction of Rev mutants. EIAV Rev cDNA deletion mutants were
generated in the previously described plasmid pRevWT (7). Rev mutants
containing internal deletions were constructed by PCR-ligation-PCR mutagenesis as described by Ali and Steinkasserer (3). Briefly, upstream and
downstream blunt-ended cDNA fragments of each mutant were amplified
from pRevWT using the primers designed from the EIAV Wyoming cell
culture-adapted isolate (GenBank accession no. M16575) (27). Specific
primer sequences used for cloning are available upon request. Fragments
were gel purified, and downstream fragments were phosphorylated and ligated to the corresponding upstream fragment. Ligation products were amplified by PCR using wild-type 5⬘ (CAGCATGGCAGAATCGAAGG) and
wild-type 3⬘ (CGAGAGTTCCTTCTTGGGA) primers. Following the second
PCR, the cDNAs were TA cloned into pCR3.1 (Invitrogen, Carlsbad, CA)
and transformed into Escherichia coli DH5-␣, and transformants were
screened by colony blot hybridization. The C-terminal deletion mutants were
PCR amplified using the 5⬘ wild-type flanking primer and unique 3⬘ primers
that generated premature stop codons. PCR was performed using standard
methods, and cDNAs were TA cloned into pCR3.1 as described above.
Site-specific mutations were introduced by PCR-based mutagenesis. All constructs were confirmed by sequencing, and protein expression was verified by
Western blotting using EIAV convalescent horse sera (10).
Rev fusion proteins. To construct green fluorescent protein (GFP) fusion
proteins, Rev sequences were PCR amplified from wild-type and deletion constructs with primers that introduced 5⬘ EcoRI and 3⬘ BamHI restriction sites.
PCR products were digested with EcoRI and BamHI and cloned into the GFP
expression vector pEGFP-C2 (Clontech, Palo Alto, CA). The C-terminal region
of Rev (specifying amino acids 145 to 165) was synthesized as complementary
oligonucleotides that created 5⬘ EcoRI and 3⬘ BamHI overhangs after annealing.
Wild-type and mutant oligonucleotides were synthesized, annealed, digested
with EcoRI and BamHI, and cloned into similarly restricted pGFP-RDM12. All
plasmids were sequenced to verify that each mutant Rev was translated from a
single open reading frame.
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A series of maltose-binding protein (MBP)-Rev fusion proteins were used for
RNA-binding studies. ERev fragments amplified from EIAV R1A (6) or Rev
cDNA plasmids were cloned in pHMTc (43), which is based on the pMal-c2x
expression vector (New England Biolabs, Beverly, MA). For most MBP-ERev
constructs, Rev cDNA templates were amplified from EIAV variant R1A;
MRD8 contains the Rev deletion mutant RDM11, which is based on pRevWT
(see above). MBP-ERev constructs containing point mutations were cloned using
amplified mutated PCR fragments based on R1A Rev cDNA template. All
plasmid constructs were confirmed by DNA sequence analysis.
CAT assays. Rev nuclear export activity was quantified in transient transfection assays using a pDM138-based EIAV Rev reporter construct, pERRE-All, as
previously described (7). 293T cells were seeded in triplicate at 1 ⫻ 105 to 5 ⫻
105 cells/well in 6-well tissue culture dishes and maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS)
and penicillin-streptomycin (P-S) at 37°C and 8% CO2. One day after seeding,
cells were transfected with 1.0 g Rev cDNA or empty vector, 0.2 g pERRE-All
reporter plasmid DNA, 0.2 g beta-galactosidase reporter plasmid DNA, and
sufficient pUC19 to bring each well to 2.0 g total transfected DNA. Medium was
changed the next day, and cells were harvested at 48 h posttransfection, lysed by
freezing-thawing, and normalized for transfection efficiency by measuring betagalactosidase activity as described previously (7). Cell lysates were assayed for
␤-galactosidase activity and normalized reaction volumes were assayed for chloramphenicol acetyltransferase (CAT) enzyme activity or for CAT protein using
thin-layer chromatography or a commercial CAT enzyme-linked immunosorbent
assay kit (Roche Molecular Biochemicals, Indianapolis, IN), respectively (7, 8).
All assays were performed in triplicate, and results represent at least six independent transfections. Statistical analysis was performed using analysis of variance and Student’s t test assuming unequal variance among groups.
Trans-complementation assays. Cf2Th (ATCC no. CRL-1430) clonal cell lines
containing Rev (⫹) or Rev (⫺) EIAV proviral DNA were used to characterize
nuclear export activity (7). Cf2Th/112 cells contain a Rev-competent proviral
clone and produce supernatant reverse transcriptase (RT) activity, viral structural proteins, and all classes of viral mRNAs. Cf2Th/51 cells contain Revdefective proviral DNA, express only fully spliced mRNA, and lack detectable
levels of viral structural proteins or RT activity. Trans-complementation of
Cf2Th/51 cells with Rev cDNA results in viral protein expression and RT activity
(7). Cells were seeded at 5 ⫻ 105 cells/well in 6-well tissue culture plates and
maintained in DMEM supplemented with 10% FCS and P-S at 37°C and 8%
CO2. The next day, cells were transfected with 2 g of wild-type Rev cDNA, Rev
mutant cDNA, or empty vector DNA using the liposome-mediated transfection
reagent Lipofectamine (Invitrogen). At 3 days posttransfection, supernatant was
collected and assayed for RT activity as previously described (11).
Nuclear localization assays and microscopy. Cf2Th cells were plated at 2 ⫻
104 cells/cm2 in 6- or 24-well plates or 8-well glass chamber slides (Nunc, Rochester, NY). Twenty-four hours after plating, cells were transiently transfected
with 0.25 g GFP or GFP-Rev plasmid DNA per 2 ⫻ 104 cells using the
liposome-mediated transfection reagent TransIT-LT1 according to manufacturer
instructions (Mirus, Madison, WI). In certain experiments, replicate cultures
were treated at 20 h posttransfection with 5 nM leptomycin B (LMB) in dimethyl
sulfoxide. At 24 h after transfection, cells were fixed in 3.7% formaldehyde in 10
mM phosphate-buffered saline (PBS) for 30 min at 25°C and washed twice with
complete DMEM supplemented with 10% FCS and P-S. Nuclei of fixed cells
were stained with 0.5 g/ml Hoechst 33258 dye (Sigma, St. Louis, MO) in 0.5%
NP-40 and 10 mM PBS for 15 min at 25°C. Cells were subsequently washed twice
in complete DMEM and once in 10 mM PBS. All transfections were performed
in triplicate.
Fixed cells in 6- and 24-well plates were examined with an inverted Nikon
Diaphot fluorescence microscope with a 40⫻ objective and a 100-W high-pressure mercury lamp; epifluorescence filters were used to visualize Hoechst-stained
nuclei and GFP. For confocal microscopy, chambers were removed from slides
and a coverslip was sealed over fixed cells; slides were examined with a Leica
TCS NT laser confocal microscope using a 63⫻ oil-immersion objective; digital
filters with 400- to 480-nm and 500- to 560-nm excitation wavelengths were
necessary to visualize Hoechst-stained DNA and GFP, respectively. Brightness
and contrast of images obtained by confocal microscopy were adjusted with
Adobe Photoshop 4.0.
RNA-binding assays. MBP-Rev fusion proteins were expressed in RosettaGami DE3 (pLacI) (Novagen, Madison, WI). Harvested cells were lysed by
freezing-thawing, and His-tagged fusion proteins were purified under native
conditions using Ni2⫹-charged resin (Invitrogen). The purity of fusion proteins
was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) followed by Coomassie staining or Western blotting using EIAV
convalescent-phase sera or polyclonal antibodies directed against the His Tag
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(MBL International, Woburn, MA). Purified MBP-Rev proteins were dialyzed
and stored in 50 mM Tris-HCl (pH 8.0), 50 mM NaCl at 4°C. The EIAV
Rev-responsive element (RRE) (nucleotides 5443 to 5565) was amplified by
PCR from pERRE-All (8) using a 5⬘ primer containing a T7 promoter site. The
PCR product was purified using QIAquick PCR purification columns (QIAGEN,
Valencia, CA), and RNA was generated by in vitro transcription (T7MEGAshortscript; Ambion, Austin, TX) in the presence of [␣-32P]UTP. Transcribed radiolabeled RNA was purified on a G50 column (Roche, Indianapolis,
IN), denatured at 80°C for 5 min in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl,
annealed by slow cooling, and stored at ⫺80°C.
For RNA-binding reactions, 2 to 4 g purified MBP-Rev fusion protein was
incubated with 104 cpm of 32P-labeled EIAV RRE RNA in binding buffer (10
mM HEPES-KOH, pH 7.5, 100 mM KCl, 1 mM MgCl2, 0.5 mM EDTA, 1 mM
dithiothreitol, 50 g/ml E. coli tRNA, and 10% glycerol) for 20 min at room
temperature. After incubation, reaction samples were irradiated with 3 ⫻ 105 J
at 254 nm for 7 min. Samples were treated with 0.1 mg/ml RNase A at 37°C for
20 min; the reaction was terminated by boiling 5 min in an equal volume of SDS
and separated in SDS–12% PAGE in Tris-glycine buffer. Gels were fixed in 50%
methanol–10% acetic acid, dried, and exposed to PhosphorImager screens overnight. UV cross-linked complexes were quantified using a PersonalFX scanner
and Quantity One software (Bio-Rad, Hercules, CA).

RESULTS
Functional analyses of Rev deletion mutants. Lentiviral Rev
proteins utilize discrete functional domains to control expression of viral mRNAs and structural proteins. To aid in identification of EIAV Rev functional domains, we constructed a
nested set of Rev deletion mutants (RDM) (Fig. 2A) and
tested them for nuclear export activity in transient transfection
assays using the CAT reporter construct, pERRE-All (7). Nuclear export activity was highly sensitive to deletions in the Rev
protein (Fig. 2B, panel 1). Mutants RDM4, RDM6-RDM10,
and RDM12 showed no CAT activity, whereas activity was
significantly reduced in RDM5. Only one mutant, RDM11,
showed levels of CAT activity comparable to wild-type Rev. To
ensure that these results were not an artifact of the CAT
reporter construct, all mutants were also tested by transcomplementation of a Rev-defective clonal cell line, Cf2Th/51
(Fig. 2B, panel 2). Overall, there was good agreement between
the two assays: transfection with mutants RDM4-RDM10 and
RDM12 showed no RT activity, while cells transfected with
mutant RDM11 had activity similar to that of wild-type Rev.
Western blot analysis using anti-EIAV polyclonal horse sera
was done to confirm that all mutants expressed Rev. Some
variation in protein expression was observed; however, the
levels of expression did not correlate with levels of Rev activity.
Mutants RDM4, RDM5, RDM6, RDM11, and RDM12 expressed at levels equal to or higher than Rev-WT, while
RDM7, RDM8, and RDM10 expression levels were somewhat
lower than Rev-WT. Only RDM9 showed markedly reduced
levels of protein expression compared to other mutants. With
the exception of RDM9, therefore, the loss of nuclear export
activity was likely due to deletion of discrete functional domains and/or the loss of tertiary structure(s) required for activity.
The KRRRK motif in the C terminus of Rev is required for
nuclear localization. The highly basic C terminus of EIAV Rev
contains residues essential for nuclear entry (23); however, the
precise NLS has not been identified. To more specifically identify the amino acids necessary for nuclear localization, each of
the Rev deletion mutants shown in Fig. 2A were used to construct GFP-Rev fusion proteins. Plasmid DNA was transiently
transfected into Cf2Th cells, and subcellular localization of
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FIG. 2. Functional analyses of Rev deletion mutants. (A) Terminal
and internal deletions in Rev cDNA were generated from pRevWT by
PCR-ligation-PCR as described in the text. The region of amino acids
deleted in each cDNA is indicated. (B) Activity of Rev deletion mutants was assayed in transient expression assays. Results are reported
as activity relative to pRevWT. Cells transfected with the pCR3.1
vector DNA were used as the negative control (Neg.) in all assays.
Error bars denote the standard error of the mean. Graph 1 shows
nuclear export activity measured using a CAT reporter assay (7).
Lysates were normalized by ␤-galactosidase activity, and CAT activity
was measured as the percentage of acetylation. Individual experiments
included triplicate wells, and the data shown represent the means of at
least three separate experiments. Graph 2 shows supernatant reverse
transcriptase (RT) activity following trans-complementation of a Revdefective clonal cell line, Cf2Th/51, with Rev deletion mutants. Wt,
wild type.

fusion proteins was assessed by fluorescence and confocal microscopy. Only two of the nine GFP-Rev deletion mutants
exhibited subcellular localization patterns different from that
of wild-type Rev (data not shown). GFP-RDM4, which con-

FUNCTIONAL DOMAINS OF EIAV Rev

3847

tains a deletion in the NES, was found only in the nucleus, and
GFP-RDM12, which lacks the 21 C-terminal residues of Rev,
was found exclusively in the cytoplasm. The C terminus contains a strongly basic KRRRK motif that is similar to other
basic NLSs (22, 25, 46) and was previously suggested to be a
component of the EIAV Rev NLS (23). To identify critical
residues within the C-terminal region, we introduced additional deletions or alanine substitutions across the last seven
residues of GFP-Rev (Fig. 3A). Mutants were transfected into
Cf2Th cells and assayed for subcellular localization in the
presence and absence of leptomycin B (LMB) (Fig. 3B). Rev is
a nucleocytoplasmic shuttling protein, and LMB was used to
block export of fusion proteins once they had translocated to
the nucleus. Deletion of six (GFP-RDM13) or two (GFPRDM14) amino acids from the C terminus of EIAV Rev abrogated nuclear localization. Alanine substitution within the
KRRRK motif indicated that mutation of the middle arginine
(C3 ⫽ KRARK) or the terminal lysine (C6 ⫽ KRRRA) did
not alter nuclear import; however, Rev-GFP proteins with
alanine substitutions of any two adjacent basic residues within
amino acids 159 to 163 (C1 ⫽ AARRK, C2 ⫽ KAARK, C4 ⫽
KRAAK, C5 ⫽ KRRAA) remained in the cytoplasm. Therefore, nuclear localization was dependent on the presence of a
cluster of basic amino acids within the KRRRK motif in the
C-terminal region.
Mapping the RNA-binding domain of EIAV Rev. In HIV-1
Rev, the RNA-binding domain overlaps the NLS (24). In
EIAV Rev, however, the NLS is located in the C-terminal basic
region, while the RNA-binding domain is thought to reside
within the central region of EIAV Rev (23). To better define
the RNA-binding domain of EIAV Rev, we assessed RNA
binding activity of a series of truncated MBP-Rev deletion
(MRD) mutants in UV cross-linking assays (Fig. 4A). The
purity and integrity of the MBP-Rev fusion proteins were confirmed by SDS-PAGE (Fig. 4B). RNA-protein complexes were
observed in reactions containing either MBP-Rev or MRD1
and the sense strand of the RRE but not in reactions containing the antisense RRE RNA (Fig. 4C). RNA-protein complexes included a clearly defined, faster migrating band and
diffuse slower migrating products. No RNA-protein complexes
were observed with either bovine serum albumin or MBP,
demonstrating the specificity of Rev-RNA binding (Fig. 4C).
Our analysis of the Rev-MBP deletion mutants showed that
MRD1 and MRD3 each formed an RNA-protein complex,
indicating that neither exon 1 (amino acids [aa] 1 to 30) nor the
N-terminal leucine-rich NES (aa 31 to 56) was required for
RNA binding. Constructs lacking either the last 20 or 40 Cterminal residues (MRD2, MRD4, and MRD5) did not form a
complex with the EIAV RRE (Fig. 4D). However, no RRE
binding was detected using fusion proteins containing only
C-terminal residues (MRD6 and MRD7). Therefore, residues
within the C-terminal domain were necessary, but not sufficient, for RNA binding. To aid in identifying the boundaries of
the Rev RNA binding domain, we constructed MRD8, a mutant with an internal deletion of aa 131 to 143. This is the same
region deleted in RDM11 (Fig. 2), a deletion mutant with
wild-type levels of nuclear export activity. MRD8 bound the
RRE RNA at levels comparable to wild-type Rev and MRD1
(Fig. 4E). There appeared to be a relative increase in the
slower migrating RNA-protein complexes (compare Fig. 4E
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FIG. 3. The KRRRK motif in the C terminus of Rev is required for nuclear localization. (A) Amino acid sequence of the C terminus of
wild-type Rev (aa 144 to 165) and the location of deletions or alanine substitutions introduced into wild-type GFP-Rev mutants. (B) Subcellular
location of GFP-Rev deletion mutants (GFP-RDM13 and GFP-RDM14) and GFP-Rev containing alanine substitutions in the C terminus. Cf2Th
cells were transfected with the specified Rev-GFP cDNAs in the presence or absence of 5 nM leptomycin B (LMB). Images of fixed and stained
Cf2Th cells were obtained by confocal laser microscopy. Brightness and contrast were adjusted with Adobe Photoshop 4.0.

with C and D); however, this may be due to variability between
experiments rather than differences in Rev binding. The RNAbinding activity of MRD8, together with the lack of RNA
binding in MRD5, MRD6, and MRD7, indicate that two, noncontiguous regions of EIAV are required for RNA-binding
activity. One region encompasses aa 57 to 130, and the second
region is located in the C terminus of Rev, encompassing aa
144 to 165.
Two noncontiguous ARMs are required for RNA binding
and nuclear export activity. Arginine-rich motifs are among
the most common and well-characterized RNA-binding motifs
(9) and are essential for RNA-binding activities of HIV Rev
and Tat (24, 29, 41, 45). In HIV-1 Rev, a single 12-aa-long
ARM located within the N-terminal domain functions in both

RNA binding and nuclear localization (24). EIAV Rev contains two short Arg-rich motifs: RRDRW (aa 76 to 80) within
the central region and KRRRK (aa 159 to 163) in the Cterminal region. Another motif within the central domain,
ERLE (aa 93 to 96), was proposed as an RNA-binding motif
based on studies showing that replacement of the motif with
alanines abolished nuclear export and alternative splicing activity (23) and abrogated RNA binding in gel mobility shift
assays (14). All three motifs are located within the regions we
identified as essential for RNA-binding activity of EIAV Rev
(Fig. 4). To directly test their contribution to RRE binding, we
introduced alanine substitutions into each motif in the background of MBP Rev construct MRD1. The amount of RNAprotein complexes was greatly reduced with either MRD1-
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FIG. 4. Identification of sequences critical for RNA-binding activity of EIAV Rev. (A) MBP-Rev deletion mutants (MRD) containing 5⬘ or 3⬘
deletions used to map regions of Rev required for RNA binding. The Rev amino acids retained in each construct are indicated. (B) Expression
and purity of MRD mutants were assessed by Coomassie staining of SDS-PAGE gels. The molecular size of each deletion mutant was confirmed
using molecular size (MW) markers. (C) RNA-binding activity of MBP-Rev fusion proteins was determined by UV cross-linking and SDS-PAGE.
Rev fusion proteins were incubated with radiolabeled EIAV RRE (nucleotides 5443 to 5565), cross-linked with UV irradiation, and treated with
RNase. RNA-protein complexes were separated by SDS-PAGE and quantified using a PersonalFX scanner and Quantity One software (Bio-Rad).
Negative controls included bovine serum albumin (BSA), MBP, and antisense RRE. (D and E) RRE-binding activity of Rev deletion mutants as
described for panel C.

AADAA, where all of the residues except the Asp in the
RRDRW motif were replaced by Ala, or MRD1-KAAAK, in
which all Arg residues in the KRRRK motif were replaced by
Ala (Fig. 5A). However, near wild-type levels of RNA-protein
complexes were observed with MRD1-AALA, where the
charged residues (Arg and Glu) in the ERLE motif were replaced by Ala. Thus, Arg residues in both the RRDRW and
the KRRRK motif are essential for RNA binding. The finding
that two separate, noncontiguous Arg-rich motifs are required
for RNA binding indicates that EIAV Rev contains a bipartite
RNA-binding domain, one portion of which overlaps the nuclear localization signal. This RNA-binding arrangement of
EIAV Rev differs markedly from that of HIV-1 Rev.
Although others have reported a loss of RNA-binding activity due to alanine substitutions for the ERLE motif in the
central domain of EIAV Rev (14), we observed no decrease in
RNA binding when Ala was substituted for only the charged
residues in the ERLE motif (MRD1-AALA). This suggested

FIG. 5. RRE-binding activity and functional analyses of Rev mutants. A. Identification of specific motifs essential for RRE-binding
activity of EIAV Rev. Point mutations introduced into the RRDRW,
ERLE, and KRRRK motifs include alanine substitution of charged
and/or Arg residues (AADAA, AALA, and KAAAK) and substitution
of Asp for Leu in the ERLE motif (L95D). Binding activity was
assessed as described in the legend to Fig. 4C. B. Activity of Rev point
mutation mutants (AADAA, AALA, KAAAK, and L95D) and deletion mutant (RDM13) were assayed as described in the legend to Fig.
2B. Neg., negative control. Wt, wild type.
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that the Leu residue at position 95 was critical for the RNAbinding activity. The predicted secondary structure of EIAV
Rev, based on consensus results using five different prediction
programs (16, 28, 29, 39, 42), places the ERLE motif in the
middle of an ␣-helix, and it was previously suggested that the
Ala substitutions may disrupt the ␣-helical structure (14). To
explore this, we substituted an Asp for the Leu residue at
position 95 (L95D). The Asp can act not only as a helix breaker
but also can disrupt hydrophobic interactions between helices.
The L95D mutation resulted in an 80% reduction of the maximum binding of Rev to RRE (Fig. 5A). Therefore, the ERLE
may play a role in stabilizing the protein structure required for
RNA-binding activity.
To extend our analyses of the RRDRW and ERLE motifs,
we introduced the Ala or Asp substitutions in R1A cDNA and
analyzed the effect of mutations on Rev nuclear export activity
in transient transfection assays (Fig. 5B). All of the RRDRW
and ERLE mutants had significantly reduced Rev nuclear export activity. In addition, deletion of the KRRRK motif
(RDM13), which is required for both RNA binding and nuclear export, eliminated Rev nuclear export activity in cellbased transfection assays. The results of these functional studies support our RNA-binding studies and establish a critical
role for these motifs in Rev nuclear export activity. Interestingly, the AALA mutant was able to bind to viral RNA but was
defective for nuclear export activity. Although its exact role is
not known, this confirms previous findings that ERLE is critical for Rev activity (14, 23). More detailed analyses of RevRRE interactions will further enhance the results of our in
vitro RNA-binding assays.
DISCUSSION
The Rev/Rex proteins of complex retroviruses are essential
regulatory proteins that mediate nuclear export of incompletely spliced viral mRNAs via discrete functional domains
that interact with cellular proteins and viral RNA. This family
of proteins contains an interchangeable nuclear export signal
that interacts with the cellular protein Crm1 and an ARM that
binds specifically to homologous viral mRNA. Compared to
most lentiviral Rev proteins, EIAV Rev is atypical with respect
to the organization of functional domains (20, 23), the spacing
of critical residues in the NES (23, 33), the use of a purine-rich,
exonic splicing element as an RRE (8, 34), and the regulation
of alternative splicing of the bicistronic tat/rev mRNA (34). In
addition, EIAV Rev is highly variable in vivo, and we have
shown that changes in Rev phenotype correlate with changes in
clinical stages of EIAV infection (4, 6, 7). To better understand
the significance of Rev variation in vivo, we undertook more
detailed analyses of the functional domains of EIAV Rev.
Previous studies identified point mutations in EIAV Rev that
reduced nuclear export (7, 20, 23, 33, 35), alternative splicing
(7, 23), RNA binding (14), and nuclear localization activities
(23). Here, we extend those studies to map functional domains
and identify specific motifs that are essential for EIAV Rev
activity. All domains essential for Rev activity are contained
within the second exon of EIAV Rev (20, 23). The overall
functional organization of EIAV Rev exon 2 includes the Nterminal nuclear export signal, a large central region that contains amino acids required for RNA binding, a nonessential

region, and a C-terminal region required for both nuclear
localization and RNA binding. Two short, noncontiguous ARMs
are necessary for RNA binding: a central RRDRW motif and a
C-terminal KRRRK motif that is also essential for nuclear
localization. The bipartite ARM is unique among lentivirus
Rev proteins and provides another example of how EIAV uses
an unusual protein arrangement to carry out a common lentiviral function.
In HIV-1 Rev, the prototypical lentiviral Rev, a 17-aa ARM
is located in the N-terminal half of the protein and serves as
both a sequence-specific RNA-binding domain and the NLS
(32, 37, 40). No typical ARM is found within EIAV Rev, and
prior studies have not directly examined the RNA-binding
domain of EIAV Rev. However, previous studies have identified several mutants defective in either nuclear localization or
RNA binding (14, 23). Mutants containing alanine substitutions of 157DSKR160 (M15) or 161RR162 (M1) were defective in nuclear entry and showed reduced alternative splicing
activity (23). Alanine substitutions of 76RRDR79 (M11) and
93ERLE96 (M27) resulted in loss of nuclear export activity
(23), and the latter was defective in RNA binding and alternative splicing (14). Based on these results, it appeared that
there was no overlap between the NLS and RNA-binding domain and that the EIAV Rev RNA-binding domain was distinct from the ARMs characteristic of other complex retroviruses.
The present study is the first to directly characterize the
RNA-binding activity of EIAV Rev and provides further insight into the specific motifs essential for EIAV Rev activity.
The EIAV Rev NLS is relatively compact and requires the
KRRRK motif contained within the C terminus of Rev. Mutants that retained four or five basic residues at amino acids
159 to 163 were able to translocate to the cell nucleus (C3 and
C6), while mutants with less than four basic residues in this
motif remained in the cytoplasm (C1, C2, C4, and C5). The
KRRRK motif is similar to the arginine-rich NLSs of HIV-1
Rev and HTLV-1 Rex (32, 36, 40) and is nearly identical to the
KRRR nuclear localization motifs found in the Drosophila
melanogaster gcm gene product (1) and the RNA-binding human DEDD caspase protein (44). The ERLE and RRDR
motifs identified in previous mutants M11 and M27 (23) were
both found to be important in the RNA-binding activity of
EIAV Rev, but they act through different mechanisms. Mutations of the charged residues in the ERLE motif had no effect
on RNA binding, whereas the L95D mutation reduced binding
by more than 80%. Therefore, the ERLE motif may play a role
in stabilizing the protein structure required for binding of Rev
to the viral RNA. In contrast, the arginine residues in both the
RRDRW and KRRRK motifs were required for RNA binding,
suggesting these short ARMs directly contact the RRE. Based
on the results of our deletion analyses, other residues in the
central domain likely contribute to RNA binding through direct
contact with RNA and/or stabilization of protein structure.
Arginine rich motifs are short, arginine-containing regions
of 10 to 20 amino acids that mediate RNA binding of a number
of viral and ribosomal proteins (9). The arginine residues are
thought to play two general roles in RNA binding: first, as a
probe to search for a high-affinity binding site, and second, to
form a network of specific hydrogen bonds with the RNA
backbone and specific bases (9). In the present study, we found

VOL. 80, 2006

that RNA binding of EIAV Rev required two short ARMs
separated by 79 amino acids in the primary protein sequence.
One motif is located in the central region, and the second
overlaps with the NLS in the C terminus. The results of UV
cross-linking experiments showed that the C-terminal 20 amino
acids of EIAV Rev are required, but not sufficient, for binding to
the RRE. Importantly, site-specific mutation of arginine residues
in either the central ARM or the C-terminal ARM abolished
RRE binding. These results strongly suggest that the two ARMs
interact with the EIAV RRE in concert and thus comprise a
bipartite RNA-binding domain. Coordinated action of two, noncontiguous ARMs was also found to be necessary for binding of
hepatitis delta antigen to viral RNA (13). It is not clear how two
ARMs interact to bind viral RNA. The two domains may be in
close proximity within the three-dimensional structure of the
folded protein, where they could form a single RNA-binding
domain containing at least seven arginine residues. Alternately,
the two ARMs could interact with different regions of the viral
RNA. Further analyses of EIAV Rev-RRE interactions will
provide insight into this potentially novel class of RNA-binding
motifs.
In addition to promoting export of incompletely spliced viral
RNA, EIAV Rev regulates alternative splicing of exon 3 in the
bicistronic tat/rev mRNA (34). Exon 3 contains a purine-rich
region that binds both Rev and the SR protein SF2/ASF and
thus functions as both the EIAV RRE and an exonic splicing
enhancer (7, 21, 31). Alternative splicing, or exon 3 skipping,
likely results from competition between these two functions at
either the RNA binding step or at a downstream step involved
in spliceosomal assembly or activation (7, 14, 21, 31). Previous
studies reported a loss in alternative splicing activity in Rev
mutants containing alanine substitution of the ERLE motif or
in both the RRDR and KRRRK motifs (14). Mutational analyses of cis-acting sequences required for exon 3 skipping show
a close correlation between alternative splicing activity and
RNA-binding activity (8, 14). Together, these data suggest that
RNA binding plays an essential role in alternative splicing.
Studies to date, however, have been unable to identify an
alternative splicing domain distinct from other Rev functional
domains (23). Therefore, it has been difficult to assess the
biological significance of alternative splicing in vivo. Exon 3
skipping was originally proposed as a novel mechanism for
autoregulation of Rev (34); however, mRNAs lacking exon 3
comprise only a small percentage of viral mRNA in Rev-expressing cells (31). At present, the primary function of EIAV
Rev appears similar to other lentiviral Revs in regulating the
shift from production of multiply spliced to incompletely
spliced viral mRNAs.
There is a relatively high rate of genetic variation in the
region of the EIAV genome where the second exon of Rev
overlaps the cytoplasmic portion of the transmembrane protein gp45 (2, 6, 7, 30). The NLS and RNA-binding motifs are
highly conserved, while the region identified here as nonessential for Rev function is the site of a number of amino acid
changes that significantly altered Rev phenotypes (6). The
nonessential region spans a predicted ␣-helix, and our results
indicate that deletion of this region does not alter the structure
of the Rev in a way that compromises Rev function. Similarly,
the overlapping region of TM is found within the cytoplasmic
domain, which may also be able to accommodate some degree
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of genetic variation without loss of function. As such, this
region of the viral genome may be able to tolerate genetic
mutations in Rev and/or TM that confer a selective advantage
in vivo. Future studies may reveal how genetic variation in Rev
contributes to viral persistence while preserving the function of
this critical lentiviral protein.
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